WilmerHale Counsels Constellation Pharmaceuticals in $60M IPO

WilmerHale Counsels Constellation Pharmaceuticals in $60M IPO

Firm News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Lawyers with deep and broad experience counseling clients in every industry on the design, implementation, and interpretation of executive compensation arrangements and on general compensation and benefits issues.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, announced on July 18, 2018, the pricing of its initial public offering of 4,000,000 shares of common stock at a public offering price of $15.00 per share, for gross proceeds of $60 million.

The WilmerHale team representing Constellation is led by Lia Der Marderosian and includes Steven Singer, Craig Hilts, Caroline Dotolo, Hilary Baker-Jennings, Kimberly Wethly and Meghan Walsh.

Read Constellation’s press release about the IPO.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel